YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Amgen to buy Celgene's Otezla for $13B

Posted online

Amgen Inc. agreed to buy Celgene Corp.'s psoriasis treatment called Otezla for $13.4 billion.

The deal allows Bristol-Myers Squibb Co. to move forward on its acquisition of Celgene.

Otezla's sales were $1.6 billion last year.

Read more from The Wall Street Journal.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
2024 Most Influential Women

For 25 years, Springfield Business Journal has honored local women for their professional and civic accomplishments and contributions.

Most Read
Update cookies preferences